Form 4: Vaxcyte CEO Grant Pickering Sells Shares Under 10b5-1 Trading Plan

Vaxcyte's CEO, Grant Pickering, executed multiple sales of common stock on October 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Grant Pickering, the CEO of Vaxcyte, Inc. (PCVX), reported the sale of company stock on October 7, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on April 12, 2024.
• Multiple transactions occurred at varying weighted-average prices, ranging from approximately $107.27 to $110.35 per share.
• A total of 4,745 shares were sold directly by Pickering.
• Following the reported transactions, Pickering continues to indirectly own shares through a children's trust.
• The children's trust holds 138,581 shares for his daughter and 138,581 shares for his son.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment about the company's future.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, potentially leading to speculation about the company's future prospects, although sales under 10b5-1 plans are often pre-scheduled and not necessarily indicative of the executive's current outlook.

Future Outlook

The document does not contain any forward-looking statements regarding the company's future performance.

Industry Context

Insider trading activity is closely monitored in the biotech industry, as it can provide insights into management's confidence in the company's prospects. However, sales under pre-arranged trading plans are common and may not necessarily reflect a change in sentiment.

Stakeholder Impact

• Shareholders may react to the news of insider sales, although the existence of a 10b5-1 plan mitigates potential concerns.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal.

Key Dates